An introduction to EpiAxis
EpiAxis Therapeutics is a privately funded, leading Australian epigenetic cancer therapeutics company with a focus on the treatment, diagnosis and monitoring of cancer and prevention of cancer recurrence. Our lead program (EPI-111) targets lysine-specific demethylase 1 (LSD1) and has a dual mechanism to 1) target the dormant cancer cells that seed recurrence while also 2) reinvigorating exhausted immune cells. In addition to first-in-class assets we have dominant intellectual property covering combination treatment using LSD1 in the metastatic setting. We also have projects targeting PKC theta and PD1/PDL1.
EpiAxis was established in 2015 from research conducted by our Founding Scientist – Professor Sudha Rao, a leading epigenetic researcher. Prof Rao was initially based at the University of Canberra and is now with the QIMR Berghofer Medical Research Institute.
Our novel research focus rapidly attracted attention and we have won BioEurope Startup Slam, BioPharma Best Pitc in 2016 and were runner-up for Most Investable Company.
Clinical, pre-clinical & discovery program
EpiAxis has discovered the pivotal role that nuclear LSD1 plays in reprograming the epigenome in metastatic disease.
The people behind EpiAxis Therapeutics
EpiAxis Therapeutics is headed by CEO Jeremy Chrisp (left), pictured above with Founding Scientist Professor Sudha Rao and Chair Dr David Fuller.
While there have been tremendous recent advances in cancer treatment, there is still large unmet need, as cancer typically recurs after initial treatment due to the persistence of dormant cancer cells. Our first-in-class assets have dual action and target these dormant chemotherapy resistant cells while also improving the immune response against the persisting cells
Dr David Fuller MBBS
Chair at EpiAxis Therapeutics